

Glenmark unveils new IV injection formula for preventing chemotherapy-induced nausea and vomiting

23 January 2023 | News

AKYNZEO I.V. has been developed by Helsinn and Glenmark has exclusive marketing rights for this product in India

Glenmark Pharmaceuticals is the first to launch in India a unique I.V. injection formulation, AKYNZEO I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

AKYNZEO I.V. is a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute I.V. injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV. The drug is already being marketed in the EU, the US, and Australia.

On the occasion of the launch, Alok Malik, EVP & Business Head ? India Formulations, Glenmark Pharmaceuticals said, "Chemotherapy is the most common form of cancer treatment, with nausea and vomiting being two of its most debilitating side-effects. AKYNZEO I.V. is a convenient, single-dose, ready-to-dilute I.V. injection that covers, both, the acute and the delayed phases of CINV, thereby enabling patients to avoid multiple antiemetic drugs, and improving compliance."

Helsinn Group CEO, Giorgio Calderari, said, "AKYNZEO I.V would provide a new prophylactic option for patients in India, undergoing chemotherapy and who are at risk of CINV."

Glenmark had launched AKYNZEO Oral Capsules in 2018, the first and only CINV prevention therapy to prevent both acute and delayed phases of CINV by a single dose.